Managing the Behavioral and Psychological Symptoms of Dementia

[1]  A. Rajkumar,et al.  Systematic review of pharmacological interventions for people with Lewy body dementia , 2022, Aging & mental health.

[2]  R. Khoury,et al.  Pharmacotherapy for Frontotemporal Dementia , 2021, CNS Drugs.

[3]  B. Miller,et al.  Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms. , 2021, Brain : a journal of neurology.

[4]  E. Metzger,et al.  The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia , 2020, Psychiatry Research.

[5]  A. Boxer,et al.  FTLD Treatment: Current Practice and Future Possibilities. , 2021, Advances in experimental medicine and biology.

[6]  A. Luthra,et al.  Discontinuation of antipsychotics treatment for elderly patients within a specialized behavioural unit: a retrospective review , 2020, International Journal of Clinical Pharmacy.

[7]  H. Fillit,et al.  Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review , 2020, Journal of Alzheimer's disease : JAD.

[8]  D. Religa,et al.  Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress , 2020, Frontiers in Pharmacology.

[9]  B. Husebø,et al.  Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial. , 2020, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[10]  Alan J. Thomas,et al.  Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  K. Werheid,et al.  Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial , 2020, International Psychogeriatrics.

[12]  P. Scheltens,et al.  Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review , 2020, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[13]  Naomi Kameoka,et al.  Behavioral and psychological symptoms of dementia (BPSD) and care burden : Examination in the facility staff for elderly residents. , 2020, The journal of medical investigation : JMI.

[14]  C. Neville,et al.  Withdrawal versus Continuation of Long-Term Antipsychotic Drug Use for Behavioural and Psychological Symptoms in Older People with Dementia , 2020, Issues in mental health nursing.

[15]  M. Onofrj,et al.  The Pharmacology of Visual Hallucinations in Synucleinopathies , 2019, Front. Pharmacol..

[16]  M. Leng,et al.  Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: A systematic review and Bayesian network meta-analysis. , 2019, International journal of nursing studies.

[17]  A. Tricco,et al.  Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia , 2019, Annals of Internal Medicine.

[18]  J. Cummings,et al.  Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases , 2019, Current Psychiatry Reports.

[19]  L. Schneider,et al.  Treatment Options for Agitation in Dementia , 2019, Current Treatment Options in Neurology.

[20]  M. Schroeter,et al.  Citalopram Improves Obsessive-Compulsive Crossword Puzzling in Frontotemporal Dementia , 2019, Case Reports in Neurology.

[21]  T. Eguale,et al.  Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia , 2019, JAMA network open.

[22]  Tetsuo Shimizu,et al.  Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series , 2019, Neuropsychiatric disease and treatment.

[23]  Huayan Liu,et al.  Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis , 2019, Journal of Neurology.

[24]  A. Hartry,et al.  Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia , 2018, International journal of geriatric psychiatry.

[25]  P. Tariot,et al.  Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program , 2018, Alzheimer's Research & Therapy.

[26]  K. Putman,et al.  Factors Associated with the Caregivers’ Desire to Institutionalize Persons with Dementia: A Cross-Sectional Study , 2018, Dementia and Geriatric Cognitive Disorders.

[27]  S. Baillon,et al.  Valproate preparations for agitation in dementia. , 2018, The Cochrane database of systematic reviews.

[28]  J. Bell,et al.  Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta‐analysis , 2018, British journal of clinical pharmacology.

[29]  C. Becker,et al.  What Behavioral and Psychological Symptoms of Dementia Affect Caregiver Burnout? , 2018, Clinical gerontologist.

[30]  T. Uchihara,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium , 2018, Neurology.

[31]  S. Ralph,et al.  Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care , 2018, Journal of Alzheimer's disease reports.

[32]  B. Pollock,et al.  Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia , 2018, Journal of psychopharmacology.

[33]  P. Roberson,et al.  Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. , 2017, The American journal of psychiatry.

[34]  N. Herrmann,et al.  Pharmacological interventions for apathy in Alzheimer's disease. , 2016, The Cochrane database of systematic reviews.

[35]  M. Crotty,et al.  An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia , 2017, International Psychogeriatrics.

[36]  Lori A. Mitchell,et al.  Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors , 2017, BMC Geriatrics.

[37]  Yu-Chih Shen,et al.  Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia. , 2017, Journal of clinical psychopharmacology.

[38]  E. Ettorre,et al.  Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. , 2017, Journal of the American Medical Directors Association.

[39]  L. Rofes,et al.  Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms , 2017, European Journal of Clinical Pharmacology.

[40]  David S. Miller,et al.  Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms , 2017, Alzheimer's & dementia.

[41]  D. Aarsland,et al.  The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review , 2017, International journal of geriatric psychiatry.

[42]  A. Porsteinsson,et al.  An update on the advancements in the treatment of agitation in Alzheimer’s disease , 2017, Expert opinion on pharmacotherapy.

[43]  P. Sachdev,et al.  Halting Antipsychotic Use in Long-Term care (HALT): a single-arm longitudinal study aiming to reduce inappropriate antipsychotic use in long-term care residents with behavioral and psychological symptoms of dementia , 2017, International Psychogeriatrics.

[44]  P. Rochon,et al.  Antipsychotic Use in Dementia , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[45]  G. Hsiung,et al.  Pharmacological Therapy for Apathy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2017, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[46]  K. Marder,et al.  Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series. , 2017, Alzheimer disease and associated disorders.

[47]  A. Hofman,et al.  10-year trajectories of depressive symptoms and risk of dementia: a population-based study. , 2016, The lancet. Psychiatry.

[48]  M. Orrell,et al.  A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being , 2016, International Psychogeriatrics.

[49]  D. Gerritsen,et al.  Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study , 2016, International Psychogeriatrics.

[50]  J. Yager,et al.  The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. , 2016, The American journal of psychiatry.

[51]  R. Magierski,et al.  Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia , 2016, Expert review of neurotherapeutics.

[52]  T. Lai,et al.  The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. , 2016, Journal of affective disorders.

[53]  T. Ohnishi,et al.  The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysis , 2015, International journal of geriatric psychiatry.

[54]  G. Waldemar,et al.  Time trends in antipsychotic drug use in patients with dementia: a nationwide study. , 2015, Journal of Alzheimer's disease : JAD.

[55]  David M. Shade,et al.  Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. , 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[56]  Pierre N Tariot,et al.  Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. , 2015, JAMA.

[57]  E. Camargos,et al.  Circadian rhythm in Alzheimer disease after trazodone use , 2015, Chronobiology international.

[58]  E. Molden,et al.  Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients , 2015, Therapeutic drug monitoring.

[59]  M. O. Olde Rikkert,et al.  Tetrahydrocannabinol for neuropsychiatric symptoms in dementia , 2015, Neurology.

[60]  L. Schneider,et al.  Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. , 2015, JAMA psychiatry.

[61]  K. Gen,et al.  Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open‐label trial , 2015, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[62]  J. M. García-Alberca,et al.  Cognitive intervention therapy as treatment for behaviour disorders in Alzheimer disease: evidence on efficacy and neurobiological correlations. , 2015, Neurologia.

[63]  David M. Shade,et al.  Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. , 2014, JAMA.

[64]  G. Zhu,et al.  The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. , 2014, Journal of Alzheimer's disease : JAD.

[65]  N. Herrmann,et al.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. , 2013, The Journal of clinical psychiatry.

[66]  M. Petrovic,et al.  Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. , 2013, The Cochrane database of systematic reviews.

[67]  N. Tsuno,et al.  Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate , 2013, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[68]  S. Engelborghs,et al.  The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: A pilot study , 2013, Aging & mental health.

[69]  M. Walterfang,et al.  Topiramate for Abnormal Eating Behaviour in Frontotemporal Dementia , 2013, Behavioural neurology.

[70]  M. Rapoport,et al.  Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review , 2012, International Psychogeriatrics.

[71]  D. Devanand,et al.  Relapse risk after discontinuation of risperidone in Alzheimer's disease. , 2012, The New England journal of medicine.

[72]  B. L. Beattie,et al.  Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer’s Disease with Comorbid Depression , 2012, Drugs & Aging.

[73]  C. Lyketsos,et al.  Atypical antipsychotic use in patients with dementia: managing safety concerns. , 2012, The American journal of psychiatry.

[74]  Pamela C. Heaton,et al.  Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings , 2012, Alzheimer's & Dementia.

[75]  H. Brodaty,et al.  Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. , 2012, The American journal of psychiatry.

[76]  J. Gaugler,et al.  The problem with “problem behaviors”: a systematic review of the association between individual patient behavioral and psychological symptoms and caregiver depression and burden within the dementia patient–caregiver dyad , 2012, International Psychogeriatrics.

[77]  J. Stewart,et al.  Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. , 2012, Journal of clinical psychopharmacology.

[78]  L. Schneider,et al.  Risk of mortality among individual antipsychotics in patients with dementia. , 2012, The American journal of psychiatry.

[79]  P. Crane,et al.  Temporal relationship between depression and dementia: findings from a large community-based 15-year follow-up study. , 2011, Archives of general psychiatry.

[80]  A. Kertesz,et al.  The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. , 2011, Brain : a journal of neurology.

[81]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[82]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[83]  P. Nestor.  Reversal of abnormal eating and drinking behaviour in a frontotemporal lobar degeneration patient using low-dose topiramate , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[84]  P. Rochon,et al.  Antidepressants for agitation and psychosis in dementia. , 2011, The Cochrane database of systematic reviews.

[85]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[86]  Bob Woods,et al.  Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy , 2010, Dementia and Geriatric Cognitive Disorders.

[87]  L. Schneider,et al.  Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[88]  L. Schneider,et al.  Sertraline for the treatment of depression in Alzheimer disease. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[89]  E. Ross,et al.  Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[90]  Jessica A. Brommelhoff,et al.  Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. , 2009, Psychology and aging.

[91]  Jean F Wyman,et al.  Predictors of Nursing Home Admission for Persons with Dementia , 2009, Medical care.

[92]  D. Guay.  Inappropriate sexual behaviors in cognitively impaired older individuals. , 2008, The American journal of geriatric pharmacotherapy.

[93]  J. Grafman,et al.  Stimulant treatment of frontotemporal dementia in 8 patients. , 2008, The Journal of clinical psychiatry.

[94]  J. Lieberman,et al.  Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. , 2008, The American journal of psychiatry.

[95]  J. Streim,et al.  A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[96]  Leonardo Franklin Fontenelle,et al.  Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[97]  S. Normand,et al.  Antipsychotic therapy and short-term serious events in older adults with dementia. , 2008, Archives of internal medicine.

[98]  C. Ballard,et al.  Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.

[99]  Alan A. Wilson,et al.  Serotonin-1A receptors in frontotemporal dementia compared with controls , 2007, Psychiatry Research: Neuroimaging.

[100]  H. Blasco-Fontecilla,et al.  Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate. , 2007, Journal of clinical psychopharmacology.

[101]  J. Mintzer,et al.  Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[102]  L. Schneider,et al.  National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. , 2007, Current Alzheimer research.

[103]  J. Fisher,et al.  Meta-Analysis of the Effectiveness of Atypical Antipsychotics for the Treatment of Behavioural Problems in Persons with Dementia , 2007, Psychotherapy and Psychosomatics.

[104]  Henry Brodaty,et al.  The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta‐analysis of 4 placebo‐controlled clinical trials , 2007, International journal of geriatric psychiatry.

[105]  G. Borasio,et al.  Inappropriate sexual behaviour in a case of ALS and FTD: Successful treatment with sertraline , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[106]  M. Mendez,et al.  Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[107]  Liat Ayalon,et al.  Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. , 2006, Archives of internal medicine.

[108]  L. Schneider,et al.  Design of Depression in Alzheimer's Disease Study-2. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[109]  F. L. Rocha,et al.  An Exploratory Open-Label Trial of Ziprasidone for the Treatment of Behavioral and Psychological Symptoms of Dementia , 2006, Dementia and Geriatric Cognitive Disorders.

[110]  Pierre N Tariot,et al.  Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.

[111]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[112]  T. Robbins,et al.  Methylphenidate (‘Ritalin’) can Ameliorate Abnormal Risk-Taking Behavior in the Frontal Variant of Frontotemporal Dementia , 2006, Neuropsychopharmacology.

[113]  S. Holroyd,et al.  The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. , 2006, Journal of psychiatry & neuroscience : JPN.

[114]  Jordan Grafman,et al.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia , 2006, Neurology.

[115]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[116]  P. Deyn,et al.  Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone , 2005, Clinical Neurology and Neurosurgery.

[117]  R. Tampi,et al.  Inappropriate Sexual Behaviors in Dementia , 2005, Journal of geriatric psychiatry and neurology.

[118]  J. Shapira,et al.  Stereotypical movements and frontotemporal dementia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[119]  B. Pollock,et al.  Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. , 2004, The Journal of clinical psychiatry.

[120]  F. Pasquier,et al.  Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone , 2004, Dementia and Geriatric Cognitive Disorders.

[121]  B. Sahakian,et al.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.

[122]  Richel Lousberg,et al.  Behavioural disturbances in dementia patients and quality of the marital relationship , 2003, International journal of geriatric psychiatry.

[123]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[124]  T. Dening,et al.  Antidepressants for treating depression in dementia. , 2002, The Cochrane database of systematic reviews.

[125]  M. Mendez,et al.  Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration , 2002, American journal of Alzheimer's disease and other dementias.

[126]  J. Luxenberg,et al.  Haloperidol for agitation in dementia. , 2002, The Cochrane database of systematic reviews.

[127]  H. P. Schmitt,et al.  Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation , 2001, Acta Neuropathologica.

[128]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[129]  I. Katz.  Depression in late life: psychiatric-medical comorbidity , 1999, Dialogues in clinical neuroscience.

[130]  P. Francis,et al.  Neurochemical Features of Frontotemporal Dementia , 1999, Dementia and Geriatric Cognitive Disorders.

[131]  P. Tariot,et al.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.

[132]  J. Swartz,et al.  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.

[133]  P. Tariot.  Treatment strategies for agitation and psychosis in dementia. , 1996, The Journal of clinical psychiatry.